Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
- DOI
- 10.1016/s2468-1253(24)00317-0
- Published
- 2024-11-18
- Container
- Lancet Gastroenterol Hepatol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2468-1253-24-00317-0,
title = {Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.},
author = {D'Haens G and Taxonera C and Lopez-Sanroman A and Nos P and Danese S and Armuzzi A and Roblin X and Peyrin-Biroulet L and West R and Mares WGN and Duijvestein M and Gecse KB and Feagan BG and Zou G and Hulshoff MS and Mookhoek A and Oldenburg L and Clasquin E and Bouhnik Y and Laharie D.},
year = {2025},
journal = {Lancet Gastroenterol Hepatol},
doi = {10.1016/s2468-1253(24)00317-0},
url = {https://doi.org/10.1016/s2468-1253(24)00317-0}
}RIS
TY - JOUR TI - Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. AU - D'Haens G AU - Taxonera C AU - Lopez-Sanroman A AU - Nos P AU - Danese S AU - Armuzzi A AU - Roblin X AU - Peyrin-Biroulet L AU - West R AU - Mares WGN AU - Duijvestein M AU - Gecse KB AU - Feagan BG AU - Zou G AU - Hulshoff MS AU - Mookhoek A AU - Oldenburg L AU - Clasquin E AU - Bouhnik Y AU - Laharie D. PY - 2025 JO - Lancet Gastroenterol Hepatol DO - 10.1016/s2468-1253(24)00317-0 UR - https://doi.org/10.1016/s2468-1253(24)00317-0 ER -
APA
G, D., C, T., A, L., P, N., S, D., A, A., X, R., L, P., R, W., WGN, M., M, D., KB, G., BG, F., G, Z., MS, H., A, M., L, O., E, C., Y, B., & D., L. (2025). Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.. Lancet Gastroenterol Hepatol. https://doi.org/10.1016/s2468-1253(24)00317-0
Source records
- europe-pmc · retrieved 2026-09-27T05:04:13.013Z